CAMP4 Therapeutics Corp. (CAMP)
4.26
-0.07
(-1.62%)
USD |
NASDAQ |
Nov 11, 12:20
CAMP4 Therapeutics Shareholders Equity (Quarterly) : 107.09M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 107.09M |
| June 30, 2026 | -0.693M |
| March 31, 2026 | 30.90M |
| December 31, 2025 | 47.70M |
| September 30, 2025 | 58.67M |
| June 30, 2025 | 39.99M |
| Date | Value |
|---|---|
| March 31, 2025 | 51.57M |
| December 31, 2024 | 63.14M |
| September 30, 2024 | 3.172M |
| June 30, 2024 | 15.03M |
| March 31, 2024 | |
| December 31, 2023 | 38.42M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.387B |
| Alnylam Pharmaceuticals, Inc. | 3.604B |
| Anika Therapeutics, Inc. | 137.58M |
| Savara, Inc. | 107.85M |
| Vericel Corp. | 384.17M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 134.01M |
| Total Liabilities (Quarterly) | 26.92M |
| Debt to Equity Ratio | 0.0602 |
| Current Ratio | 6.420 |
| Net Debt Paydown Yield | 0.06% |